Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: FEV1 Clear all
Recruiting No phase listed Observational

Effectiveness of the WearME System for COPD Severity and Respiratory Function

NCT06751537
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Not listed
Lead sponsor
LASARRUS Clinic and Research Center
Industry
Eligibility
21 Years to 100 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Salisbury, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 5, 2026, 11:39 PM EDT
Not yet recruiting Not applicable Interventional

FROST-STERN Trial: A Trial of Intraoperative Cryoablation for Post Operative Pain Management After Full Sternotomy

NCT07637370
View directory record Official record
Conditions
Pulmonary Dysfunction, Median Sternotomy Recovery, Postoperative Pain
Interventions
Intercostal Nerve Cryoablation
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 5, 2026, 11:39 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
146
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 3 Interventional Results available

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

NCT00931385
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744, bi1744, Placebo, Foradil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
11
States / cities
Tampa, Florida • Overland Park, Kansas • Lafayette, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

NCT01072149
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate (FF)/GW642444 Inhalation Powder, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
DeLand, Florida • Orlando, Florida • Madisonville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 5, 2026, 11:39 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease

NCT02960503
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Azithromycin, Placebo
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

NCT03673670
View directory record Official record
Conditions
COPD
Interventions
RPL554 Suspension, Placebo, Tiotropium/olodaterol (Respimat)
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Winter Park, Florida • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 3 Interventional Results available

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

NCT00932646
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, Placebo, Foradil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Not applicable Interventional Results available

The cryoICE™ CryoAnalgesia Study For Pain Management in Post thoRacic Procedures Via intercOSTal Cryoanalgesia (FROST)

NCT02922153
View directory record Official record
Conditions
Pain
Interventions
Cryoanalgesia, Standard of Care
Device · Drug
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Ann Arbor, Michigan • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study in Subjects With Asthma

NCT00980200
View directory record Official record
Conditions
Asthma
Interventions
Dose 4 QD, Dose 3 QD, placebo, Dose 2 QD, Dose 1 BD
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Cypress, California • Huntington Beach, California • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 5, 2026, 11:39 PM EDT
Completed No phase listed Observational

Host and Bacterial Mechanisms During Cystic Fibrosis Pulmonary Exacerbations

NCT04354038
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 5, 2026, 11:39 PM EDT
Completed No phase listed Observational

Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)

NCT01797367
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, HIV
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years and older
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 5, 2026, 11:39 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02669251
View directory record Official record
Conditions
Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease, Bronchiolitis Obliterans Syndrome
Interventions
MPH966
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 5, 2026, 11:39 PM EDT
Not yet recruiting Not applicable Interventional

WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor).

NCT07430605
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
WearME-Pro Patch System, FDA-cleared handheld spirometer (reference comparator), Cardea SOLO ECG patch (optional subset; exploratory HR reference)
Device
Lead sponsor
LASARRUS Clinic and Research Center
Industry
Eligibility
21 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Baltimore, Maryland • Salisbury, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

NCT01040728
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg, Placebo (for Olodaterol (BI1744)l), Placebo (for Tiotropium)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Jasper, Alabama • Clearwater, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

NCT01685801
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo-matched-to-ivacaftor tablet
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01017952
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Not applicable Interventional

Evaluating the Effectiveness of Incentive Spirometry

NCT02952027
View directory record Official record
Conditions
Dyspnea, Respiratory Rate, Oxygen Saturation, Oxygen Requirements, FEV1, FVC, Atelectasis, Pneumonia, Re-intubation, Hospital Length of Stay, Nursing Workload, Incentive Spirometry
Interventions
Use-recording, patient-reminder alarm for incentive spirometry
Behavioral
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 2 Interventional

Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD

NCT00640484
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
carmoterol (CHF 4226), placebo, salmeterol
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 1 Interventional

Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0

NCT03226431
View directory record Official record
Conditions
Lung Transplant
Interventions
Ascorbic Acid
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 5, 2026, 11:39 PM EDT
Terminated Phase 2 Interventional

Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.

NCT00530166
View directory record Official record
Conditions
Asthma
Interventions
JNJ-18054478, sham comparator
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Scottsdale, Arizona • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Sep 5, 2026, 11:39 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF

NCT02690064
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Acute Antioxidant, Chronic Antioxidant, Placebo
Dietary Supplement · Other
Lead sponsor
Augusta University
Other
Eligibility
7 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 5, 2026, 11:39 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01009463
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
94
States / cities
Birmingham, Alabama • Jasper, Alabama • Peoria, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 5, 2026, 11:39 PM EDT